DSIP - 10ml/10mg - Spray

ADVANCED DELIVERY SYSTEM – CELL PENETRATING PEPTIDE TECHNOLOGY

This product utilizes advanced delivery technology featuring the cell-penetrating peptide Penetratin D-Arg. This system is designed to support efficient intracellular transport of active research compounds under controlled laboratory conditions.

SPECIFICATIONS

Product Code: DSI010S

Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Molecular Formula: C35H48N10O15

Molecular Weight: 848.824 g/mol

CAS Number: 62568-57-4

Purity: Technical / Research Grade ≥98%

Other Details: No TFA Salt

Form: Liquid solution

Appearance: Clear to slightly opalescent

Total Content: 10 mL / 10 mg

Concentration: 1 mg/mL

Total Spray: 82 (approx. 122 mcg per spray)

Vehicle / Carrier System: Purified water, PEG-based carrier system, stabilizers, preservatives

Storage: 4°C. Do not freeze.

Source: Synthetic

Safety Classification: Standard laboratory handling

DESCRIPTION

Delta sleep-inducing peptide (DSIP) was first isolated in 1977 from mammalian brain tissue. It is a naturally occurring nonapeptide that has been investigated in experimental models for its involvement in sleep regulation and circadian rhythm modulation.

Research literature describes DSIP as being associated with delta-wave activity in electroencephalographic (EEG) recordings. Endogenous DSIP concentrations appear to fluctuate in a diurnal pattern, with measurable variations observed between morning and afternoon plasma levels in human studies.

Experimental findings suggest that DSIP may interact with mechanisms involved in sleep–wake regulation, particularly under conditions of sleep disruption. In healthy subjects without sleep disturbances, reported physiological effects have generally been minimal.

DSIP has also been explored in preclinical and exploratory clinical settings in relation to circadian rhythm modulation, stress response, and sleep architecture.

Additional laboratory investigations have examined its interaction with monoamine oxidase type A (MAO-A) activity and serotonergic pathways under hypoxic or stress-related conditions.

Preclinical models have also evaluated DSIP in relation to nociceptive signaling, mitochondrial respiration, and oxidative stress parameters, focusing on mechanistic insights rather than therapeutic application.

Altered DSIP-like immunoreactivity has been reported in certain psychiatric research contexts, including studies examining depressive disorders and stress-associated sleep disturbances.

Overall, DSIP continues to be studied as a research peptide for understanding regulatory mechanisms involved in sleep modulation, neurochemical balance, and cellular stress response.

REFERENCES

F. Bes et al., "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study" [PubMed]

E.M. Khvatova et al., "Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress" [PubMed]

A. Nakamura et al., "Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP)" [PubMed]

D. Schneider-Helmert et al., "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior" [PubMed]

D. Schneider-Helmert & G.A. Schoenenberger, "The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep" [SpringerNature]

D. Schneider-Helmert, "Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia" [PubMed]

B.J. Pollard et al., "Delta sleep-inducing peptide" [European Journal of Anaesthesiology]

A. Westrin et al., "High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder" [PubMed]

H. Walleus et al., "Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients" [Nordisk Psykiatrisk Tidsskrift]

E.M. Khvatova et al., "Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia" [PubMed]

W. Larbig et al., "Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study" [PubMed]

A. Bjartell et al., "Delta sleep-inducing peptide (DSIP): An overview of central actions and possible relationship to psychiatric illnesses" [Nordisk Psykiatrisk Tidsskrift]

DISCLAIMER

This product is intended strictly for laboratory research and development use only. It is not a medicine, pharmaceutical product, or dietary supplement.

This substance has not been evaluated or approved by the FDA, EMA, or any other regulatory authority for the prevention, treatment, or diagnosis of any disease.

Bodily introduction into humans or animals is strictly prohibited. This product must be handled exclusively by qualified laboratory professionals.

All information provided is for scientific and educational purposes only.